AI Drug Race Heats Up, but the Real Battlefield Is Not Algorithm Slogans

The race to develop AI-driven new drugs is heating up, but the focus may not be on who has the flashiest model. For pharmaceutical companies and investors, the real dividing line is shifting toward a more basic and more difficult question: whether the molecules proposed by algorithms can be synthesized in the laboratory, hold up in animal and cell models, and ultimately enter human trials and regulatory review.

A report published by MedCity News on June 30 noted that competition in AI drug discovery is intensifying in ways that differ from common assumptions. Because the currently available public summary does not list specific companies, deal amounts, drug candidates, or clinical data, this information is better understood as an observation of industry trends, rather than as evidence that a particular drug or platform has achieved a key medical breakthrough.

In biomedical settings, AI is not used only to “find drugs.” It may be used to screen targets, predict the binding of proteins and small molecules, design antibodies or protein drugs, optimize ADMET properties, and even reanalyze existing data to look for therapeutic clues suited to specific patient populations. Each step requires different types of data and carries different costs of failure; a high score produced by a model on a screen cannot be directly equated with a usable drug.

This is also why AI drug discovery companies have gradually changed their narratives in recent years. In the early market, claims about “shortening R&D timelines” or “reducing costs” were easy to attract attention. What is now being scrutinized more closely is whether candidate molecules actually enter wet-lab validation, whether they can generate reproducible pharmacological signals, and how data, patents, and decision-making authority are arranged when working with traditional pharmaceutical companies. If the race becomes more intense, it does not necessarily mean that more companies are making bigger promises; it may mean that more platforms are being forced to produce evidence closer to the realities of drug development.

The limitations are equally clear. AI models are often constrained by biases in training data, the difficulty of externally validating nonpublic data, the gap between disease models and human biology, and downstream thresholds in drug manufacturing and toxicological safety. Even if AI can propose novel structures, preclinical research, human trials, and regulatory review will still center on verifiable safety and efficacy, rather than treating the model architecture itself as a pass.

Background Context

Recent news about AI and new drug development has appeared frequently, spanning algorithm competitions, nanobody design, and earlier intervention in reviews of drug manufacturing, showing that the industry is moving from “model demonstrations” toward “R&D process integration.” These developments differ from one another: some remain at the collaboration or competition stage, while others are beginning to touch clinical trials and supply chain issues. Viewed together, the value of AI will not be determined by a single model alone, but will be jointly shaped by data quality, experimental validation, manufacturing feasibility, and regulatory acceptance.

Therefore, the intensifying AI drug race should not be interpreted as meaning that drug development is about to become fully automated. More precisely, this is a long-distance race that brings computational power deep into biological uncertainty. The companies that run fastest may not be those best at promoting AI, but those that can turn model outputs into testable drug candidates and continue making corrections across an R&D chain with an extremely high failure rate.